Universal Anti-Tag Antibody System for Multi-Pathogen Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production and storage of antibodies for therapeutic use are costly and time-consuming, with a short shelf life, making it challenging to stockpile enough for large populations and requiring multiple antibodies to target different pathogens or toxins effectively.
Innovation Solution
The use of binding agents with a common epitopic tag and a single anti-tag antibody, which can bind to multiple binding agents, allowing for efficient treatment of various disease agents with a single therapeutic agent, reducing production and storage costs, and extending shelf life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple different therapeutic antibodies are produced and stored for different pathogens, then therapeutic efficacy against multiple disease agents is improved, but production cost and storage complexity increase significantly
Solution Approach 1:
The patent creates a universal antibody system where a single anti-tag antibody can bind to multiple different binding agents (anti-idiotype antibodies) that target different pathogens. This allows one antibody preparation to provide therapeutic coverage against multiple disease agents including viruses, bacteria, and toxins, eliminating the need to produce and store separate antibody preparations for each pathogen.
Solution Approach 2:
The patent introduces a tag structure as an intermediary element. The binding agents (anti-idiotype antibodies) are engineered to contain this common tag, and the anti-tag antibody recognizes and binds to this tag. This intermediary tag system enables the anti-tag antibody to indirectly target multiple different pathogens through its binding to the various tagged binding agents, simplifying the therapeutic system.
2Adaptability or versatility
If multiple different therapeutic antibodies are produced for different pathogens, then coverage of multiple disease agents is improved, but production time and cost increase
Solution Approach 1:
The patent employs preliminary action by pre-engineering binding agents (anti-idiotype antibodies) with embedded tags before they are needed for therapeutic use. These tagged binding agents can be produced in advance and stored, allowing rapid deployment of therapeutic antibodies when outbreaks occur, as the anti-tag antibody can immediately bind to the pre-prepared tagged binding agents without requiring de novo production for each pathogen.
Solution Approach 2:
The anti-tag antibody serves as a universal therapeutic agent that can treat multiple different diseases by binding to various tagged binding agents, each specific to different pathogens. This eliminates the need to develop and produce separate therapeutic antibodies for each pathogen, dramatically reducing production time and enabling rapid response to emerging diseases.
3Reliability
If multiple therapeutic antibodies are stockpiled for large populations, then protection against outbreaks is improved, but storage space and maintenance requirements increase
Solution Approach 1:
The patent merges multiple pathogen-specific binding agents into a single therapeutic formulation by using a common anti-tag antibody that recognizes the shared tag structure. Instead of stockpiling separate antibody preparations for each pathogen, the system combines multiple binding agents with identical tags, allowing a single stockpiled anti-tag antibody to provide protection against multiple pathogens, thereby reducing storage space requirements.
4Reliability
If traditional antibody production methods are used for each pathogen, then specific therapeutic activity is achieved, but production cost and complexity increase
Solution Approach 1:
The patent uses copying by creating binding agents (anti-idiotype antibodies) that replicate the antigen-binding specificity of original antibodies but include an additional common tag structure. These copied binding agents can be produced more easily and cheaply using recombinant DNA technology, and when combined with the anti-tag antibody, they provide the same therapeutic activity as traditional antibodies while reducing production costs and simplifying manufacturing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables effective treatment of multiple disease agents with a single anti-tag antibody, improving therapeutic efficacy, reducing production costs, and extending the shelf life of antibody therapies, making it feasible to stockpile for large populations and rapid development of antitoxins.
Implementation Method 1
The binding region of the binding agent is specific to a portion of the disease agent. The binding agent binds to a portion of the disease agent (e.g., the target)
Implementation Method 2
the anti-tag antibody binds to the tag of the binding agent. Accordingly, the anti-tag antibody, which is directed to the disease agent by the binding agent, provides the effector activity that leads to a therapeutic effect
Data Source
AI summary
The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM.). Disease agents include bacterial proteins, viral proteins, cancer cells, and proteins or toxins produced therefrom. In particular, the present invention includes methods and systems for binding agents that are specific to neurotoxins that cause botulism.